Evidence map›Paper›PMID 39915542›Full record

ArticleBone marrow transplantation2025

Life 2.0: a comprehensive cross-sectional profiling of long-term allogeneic hematopoietic cell transplantation survivors compared to a matched general population cohort.

Hélène Schoemans, Kathy Goris, Steffen Fieuws, Koen Theunissen, Kristel Buvé, Liesbet Lammertijn, Greet Bries, Hilde Demuynck, Vincent Maertens, Helena Maes and 10 more

Abstract read
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Hélène SchoemansDepartment of Hematology, University Hospitals Leuven, Leuven, Belgium. Helene.schoemans@uzleuven.be.ORCID http://orcid.org/0000-0002-7568-8239
Kathy GorisDepartment of Hematology, University Hospitals Leuven, Leuven, Belgium.
Steffen FieuwsL-BioStat, KU Leuven-University of Leuven & Universiteit Hasselt, Leuven, Belgium.
Koen TheunissenDepartment of Hematology, Jessa Ziekenhuis, Campus Virga Jesse, Hasselt, Belgium.
Kristel BuvéDepartment of Hematology, Jessa Ziekenhuis, Campus Virga Jesse, Hasselt, Belgium.
Liesbet LammertijnDepartment of Hematology, Jessa Ziekenhuis, Campus Virga Jesse, Hasselt, Belgium.
Greet BriesDepartment of Hematology, AZ Herentals, Herentals, Belgium.
Hilde DemuynckDepartment of Hematology, Jan Yperman Ziekenhuis, Ieper, Belgium.
Vincent MaertensDepartment of Hematology, Imeldaziekenhuis, Bonheiden, Belgium.
Helena MaesDepartment of Hematology, Imeldaziekenhuis, Bonheiden, Belgium.
Stef MeersDepartment of Hematology, AZ Klina, Antwerpen, Belgium.
Christine SchuermansDepartment of Hematology, GZA St. Augustinus, Antwerpen, Belgium.
Inge VrelustDepartment of Hematology, AZ Turnhout, Turnhout, Belgium.
Hadewijch De SamblanxDepartment of Hematology, Ziekenhuis Geel, Geel, Belgium.
Griet HuysmansDepartment of Hematology, AZ Nikolaas, Sint-Niklaas, Belgium.
Vibeke VergoteDepartment of Hematology, University Hospitals Leuven, Leuven, Belgium.
Marielle BeckersDepartment of Hematology, University Hospitals Leuven, Leuven, Belgium.
Johan MaertensDepartment of Hematology, University Hospitals Leuven, Leuven, Belgium.ORCID http://orcid.org/0000-0003-4257-5980
Sabina De GeestDepartment of Public Health and Primary Care, Academic Centre for Nursing and Midwifery, KU Leuven, Leuven, Belgium.
Fabienne DobbelsDepartment of Public Health and Primary Care, Academic Centre for Nursing and Midwifery, KU Leuven, Leuven, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Long-term survivors after allogeneic cell transplantation (HCT) have unique needs. We performed a cross-sectional case-control study to describe the survivorship profile of 244 adult allogeneic transplantation recipients at a median of 8.4 years post-HCT and compared it to controls from the general population (matched 1:3 based on age, gender, and province of residence). The most prevalent medical complications were graft versus host disease (46.7%), impaired kidney function (63.9%), and the presence of a metabolic syndrome (33.6%). Survivors were significantly more likely to report a sub-optimal perceived health status than controls (82.0% versus 52.1% respectively, OR 4.57, p < 0.0001). They also reported significantly lower employment rates (42.6% versus 55.6% respectively, OR 0.389, p < 0.0001) and more polypharmacy (32.0% versus 9.6% respectively, OR 5.0, p < 0.0001) than matched counterparts. Social support and mental health were generally preserved. Apart for a concerning tendency to medication non-adherence, low physical activity (54.5%), and inappropriate exposition to UV (44.7%), health-related behavior was adequate. Many survivors have a health status comparable to chronically ill patients and, if so, should be managed as such. Novel patient-centered initiatives based on chronic care models could support survivors in preventing and dealing with long-term complications, regaining functionality, and returning to their role in society.

Indexed as

Hematopoietic Stem Cell TransplantationSurvivorsAdultAgedCase-Control StudiesCross-Sectional StudiesFemaleGraft vs Host DiseaseHumansMaleMiddle AgedTransplantation, Homologous

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.